Posted inNews and Updates
FDA Grants Priority Review for Gazyva in Kidney Disease
The FDA has granted Priority Review to Gazyva for Primary Membranous Nephropathy. Explore how this CD20-directed therapy could transform kidney care.
Posted inNews and Updates
Zemprocitinib Phase III Trial: New Hope for Ankylosing Spondylitis
Lynk Pharmaceuticals completes enrollment for its Phase III trial of Zemprocitinib, a promising new JAK inhibitor for treating Ankylosing Spondylitis.
Posted inNews and Updates
Veradermics Reveals Phase 2 Data for Hair Loss Drug VDPHL01
Veradermics announces Phase 2 results for VDPHL01, a potential new treatment for mild-to-moderate female pattern hair loss. Get the latest clinical trial data.
Posted inNews and Updates
WHO Launches Global Clinical Trial for Ebola Antiviral
The WHO has launched the first clinical trial to test an antiviral for the deadly Bundibugyo Ebola strain. Discover the impact on future outbreak control.
Posted inNews and Updates
Brain-Computer Interface Restores Speech for Paralyzed Man
A groundbreaking brain-computer interface has restored natural speech for a paralyzed patient, marking a major leap in neurotechnology and medical care.
Posted inNews and Updates
Leqembi Study: 75% of Early Alzheimer’s Patients Stable
New LEADER study data reveals that 75% of early Alzheimer's patients on Leqembi remained stable, with some showing improvement after 17 months of treatment.
Posted inNews and Updates
Diranersen Shows Promise in Phase 2 Alzheimer’s Trial
New Phase 2 data for diranersen shows significant tau reduction in early Alzheimer's patients. Explore the clinical impact and future of this ASO therapy.
Posted inNews and Updates
New Bifidobacterium Oral Vaccine Boosts Anti-Tumor Immunity
Researchers report that a new Bifidobacterium-based oral vaccine successfully boosts anti-tumor immunity by activating CD8+ T-cells against cancer cells.
Posted inNews and Updates
Clinical Trial Recruitment Stalls Due to Site Inefficiencies
Over 50% of clinical trial sites are facing major recruitment delays. Discover how operational inefficiencies are stalling drug development timelines today.
Posted inNews and Updates
Skyhawk Expands Huntington’s Disease Trial for SKY-0515
Skyhawk Therapeutics expands the FALCON-HD trial for SKY-0515 to the US, Canada, and UK, targeting the root cause of Huntington’s disease via RNA modulation.